EZH2 and synovial sarcoma: Agents that have shown anti-tumour activity in later lines in SS include trabectedin [18], pazopanib [19], regorafenib [20] and anlotinib [21] while immunotherapy and EZH2 inhibitors have produced dismal results [13, 22].